Editas Medicine
EDIT
234 hedge funds and large institutions have $384M invested in Editas Medicine in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 69 increasing their positions, 60 reducing their positions, and 43 closing their positions.
25% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $4.54M
15% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 60
2.6% less ownership
Funds ownership: 78.6% → 76% (-2.6%)
6% less funds holding
Funds holding: 250 → 234 (-16)
17% less capital invested
Capital invested by funds: $465M → $384M (-$80.9M)
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$7.19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.14M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.05M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.73M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$9.76M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.41M |
| 3 |
Millennium Management
New York
|
-$7.63M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.79M |
| 5 |
Man Group
London,
United Kingdom
|
-$3.64M |
EDIT Hedge Fund Activity: Q1 2023 in Review
234 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2023, worth a combined $384M — down 17% from $465M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of EDIT and 30 opened new positions — a net loss of 13 holders — while 60 trimmed existing stakes and 69 added.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $7.19M. The largest seller was Capital World Investors, exiting entirely with an estimated $9.76M sold.
- 234 institutional investors held Editas Medicine (EDIT) as of Q1 2023, down from 250 in Q4 2022.
- Funds reported $384M of Editas Medicine stock for Q1 2023, down 17% quarter-over-quarter.
- 30 funds opened new Editas Medicine positions in Q1 2023 and 43 closed out, a net change of -13 holders.
- The largest Editas Medicine buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $7.19M added.
- The largest Editas Medicine seller in Q1 2023 was Capital World Investors, an estimated $9.76M sold.
Based on aggregated 13F filings for Q1 2023.